Put companies on watchlist
Gerresheimer AG
ISIN: DE000A0LD6E6
WKN: A0LD6E
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

Gerresheimer AG · ISIN: DE000A0LD6E6 · EQS - Company News (54 News)
Country: Germany · Primary market: Germany · EQS NID: 1352895
16 May 2022 10:00AM

Gerresheimer AG: Gerresheimer executes on its growth strategy in Emerging Markets boosting capacities in India


DGAP-News: Gerresheimer AG / Key word(s): Miscellaneous
Gerresheimer AG: Gerresheimer executes on its growth strategy in Emerging Markets boosting capacities in India

16.05.2022 / 10:00
The issuer is solely responsible for the content of this announcement.



Gerresheimer executes on its growth strategy in Emerging Markets boosting capacities in India

Duesseldorf/Kosamba, May 16, 2022. Gerresheimer has significantly ramped up its glass and plastic production capacities in India to satisfy its global pharma customer needs. A new modern plant to produce high quality plastic containers and closures was built at the Kosamba site, and glass production received a new state-of-the-art and sustainable furnace technology. This is in line with the company's formula G growth strategy.

By adding capacities in India, Gerresheimer executes on its growth strategy in Emerging Markets addressing the global mega trend for increasing health care access in these markets and the rising demand for vaccination. Being a leading partner for global pharma and healthcare customers, Gerresheimer already operates in India. The new production capabilities combine the company’s know how and network in glass and plastic, offering solutions alongside the broad Gerresheimer portfolio.

“With our outstanding portfolio in pharma and healthcare solutions, Gerresheimer is contributing to the health and well-being of millions of patients worldwide. India is one of the strongest growing country within the Emerging Markets and a core market of large global pharma companies”, CEO Dietmar Siemssen said. "Our new facilities in India are another important step to serve global pharma customers locally as a one stop shop – with the highest quality and availability."

Gerresheimer follows a clear roadmap for further global capacity increases alongside its holistic capital allocation process. The capacity increase in India is part of Gerresheimer’s investment program to sharpen the company’s growth and return profile. Over the previous two years, the company invested a double digit million Euro amount into new furnaces in Kosamba with the latest glass melting technology.

The new state of the art furnace is equipped with newest production machines also having most sensitive inspection equipment following the Gerresheimer molded glass production standards. With this technology, the company will substantially enhance its product quality. New lines for glass injection vials as well as solid plastic dosages, closures and security systems have also been ramped up.

Further enhancing Gerresheimer’s local production and sales footprint in Emerging Markets is part of the company’s regional expansion plans. With that, Gerresheimer is well positioned for being global partner for pharma solutions and platforms.

Contact Press
Ueli Utzinger
Group Senior Director Marketing & Communication
T +41 79 400 86 40
ueli.utzinger@gerresheimer.com

Contact Investor Relations
Carolin Nadilo
Corporate Senior Director Investor Relations
T +49 211 6181-220
carolin.nadilo@gerresheimer.com

About Gerresheimer

Gerresheimer is the global partner for pharmaceutics, biotech, healthcare, and cosmetics with a very broad product range for pharmaceutical and cosmetic packaging solutions and drug delivery systems. The company is an innovative solution provider from concept to delivery of the end product. Gerresheimer achieves its ambitious goals through a high level of innovative strength, industrial competence and concentration on quality and customer focus. In developing innovative and sustainable solutions, Gerresheimer relies on a comprehensive international network with numerous innovation and production centers in Europe, America and Asia. Gerresheimer produces close to its customers worldwide with around 10,000 employees and generated annual revenues in 2021 of around EUR 1.5b. With its products and solutions, Gerresheimer plays an essential role in people's health and well-being.

 



16.05.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Gerresheimer AG
Klaus-Bungert-Str. 4
40468 Düsseldorf
Germany
Phone: +49-(0)211/61 81-314
Fax: +49-(0)211/61 81-121
E-mail: carolin.nadilo@gerresheimer.com
Internet: http://www.gerresheimer.com
ISIN: DE000A0LD6E6
WKN: A0LD6E
Indices: MDAX (Aktie)
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1352895

 
End of News DGAP News Service

1352895  16.05.2022 

fncls.ssp?fn=show_t_gif&application_id=1352895&application_name=news&site_id=boersengefluester_html
Visual performance / price development - Gerresheimer AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.